

Form PTO-1449

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary) APR 01 2002



Docket Number 432722002601

Application Number 10/050,425

Applicant

Gregory R. MUNDY *et al.*

Filing Date January 15, 2002

Group Art Unit 1600

Mailing Date March 22 2002

RECEIVED  
APR 03 2002  
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
RG	1.		09/096,631				June 12, 1998
	2.	8/1988	4,761,471	Urist	530	350	
	3.	1/1994	5,280,040	Labroo <i>et al.</i>	514	457	
	4.	12/1996	5,580,854	Orlowski <i>et al.</i>	514	18	
	5.	3/1998	5,728,844	Muller <i>et al.</i>	548	472	
	6.	6/1998	5,767,152	Nielsen <i>et al.</i>	514	526	
	7.	7/1998	5,780,454	Adams <i>et al.</i>	514	64	
	8.	10/1998	5,824,643	Pierce <i>et al.</i>	514	12	
	9.	6/1999	5,910,497	Durette <i>et al.</i>	514	253	
✓	10.	7/2000	6,083,690	Harris <i>et al.</i>	435	6	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
RG	11.	10/1990	WO 90 11366	WIPO			
	12.	3/1992	WO 92 03125	WIPO			
	13.	10/1993	WO 93 20859	WIPO			
	14.	9/1995	WO 95 24211	WIPO			
	15.	9/1995	WO 95 25533	WIPO			
	16.	12/1996	WO 96 38590	WIPO			
	17.	3/1997	WO 97 09315	WIPO			
	18.	5/1997	WO 97 15308	WIPO			
	19.	7/1997	WO 97 23457	WIPO			
	20.	10/1997	WO 97 38699	WIPO			
	21.	12/1997	WO 97 48694	WIPO			
	22.	4/1998	WO 98 17267	WIPO			
✓	23.	6/1998	WO 98 25460	WIPO			

EXAMINER:

*R. G. Gromer*

DATE CONSIDERED:

*6/25/03*

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

APR 01 2002

U.S. PATENT &amp; TRADEMARK OFFICE

Docket Number 432722002601

Application Number 10/050,425

Applicant

Gregory R. MUNDY *et al.*

Filing Date January 15, 2002

Group Art Unit 166

Mailing Date March 22, 2002

RECEIVED

APR 03 2002

RG	24.	1/2000	WO 0002548	WIPO	/	/	TECH CENTER 1600
	25.	10/1998	DE 197 16 713	Germany	/	/	2900
	26.	7/1999	EP 0 931 544	Europe	/	/	
	27.	4/1993	JP 05 097697	Japan	/	/	

## OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
RG	28.	Abu-Amer <i>et al.</i> , "NF- $\kappa$ B and Bone: The Breaking Point," NATURE MEDICINE (1997) 3(11):1189-1190
	29.	Adams, J. <i>et al.</i> , "Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents," CANCER RES (1999) 59:2615-2622
	30.	Adams <i>et al.</i> , "Chapter 28. Novel Inhibitors of the Proteasome and their Therapeutic Use in Inflammation," ANNUAL REPORTS IN MEDICINAL CHEMISTRY (1996) 279-288
	31.	Ahmed <i>et al.</i> , "Alopecia Universalis Associated with a Mutation in the Human Hairless Gene," SCIENCE (1998) 279:720-724
	32.	Bangham <i>et al.</i> , "Diffusion of Univalent Ions Across the Lamellae of Swollen Phospholipids," J MOL BIOL (1965) 23:238-252
	33.	Barnes <i>et al.</i> , "Nuclear Factor - $\kappa$ B - A Pivotal Transcription Factor in Chronic Inflammatory Diseases," NEW ENGL J MED (1997) 336:1066-1071
	34.	Baumeister <i>et al.</i> , "The Proteasome:Paradigm of a Self-Compartmentalizing Protease," CELL( 1998) 92:367-380
	35.	Beck <i>et al.</i> , "Rapid Publication TGF- $\beta$ 1 Induces Bone Closure of Skull Defects," J BONE MINER RES (1991) 6(11):1257-1265
	36.	Bellows <i>et al.</i> , "Determination of the Capacity for Proliferation and Differentiation of Osteoprogenitor Cells in the Presence and Absence and Absence of Dexamethasone," DEVELOP BIOL (1990) 140:132-138
	37.	Blessing <i>et al.</i> , "Transgenic Mice as a Model to Study the Role of TGF- $\beta$ -Related Molecules in Hair Follicles," GENES AND DEVELOP (1992) 7:204-215
	38.	Burgener <i>et al.</i> , "Fluoride Increase Tyrosine Kinase Activity in Osteoblast-like Cells: Regulatory Role for the Stimulation of Cell Proliferation and Pi Transport Across the Plasma Membrane," J BONE MINER RES (1995) 10:164-171
	39.	Caplan, "Mesenchymal Stem Cells" J ORTHOP RES (1991) 9:641-650
↓	40.	Casez <i>et al.</i> , "Dual-Energy X-Ray Absorptiometry for Measuring Total Bone Mineral Content in the

EXAMINER: *R. Gitomer*DATE CONSIDERED: *6/25/03*

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 432722002601	Application Number 10/050,425
<b>INFORMATION DISCLOSURE CITATION</b> <b>IN AN APPLICATION</b>		
<i>(Use several sheets if necessary)</i>		
		
<b>RECEIVED</b> <b>APR 03 2002</b> <b>TECH CENTER 1600</b>		

RECEIVED  
APR 10 1985

~~APR 03 2001~~

Unit 1646 3/2008  
TECH CENTER 1600/00

ENTER 1600/2900

#### **anorexia: Pentoxifylline Bearing Beta," MOL**

		Rat:Study of Accuracy and Precision," BONE AND MINER (1994) 26:61-68
126	41.	Combaret, L. <i>et al.</i> , "Manipulation of the Ubiquitin-Proteasome Pathway in Cachexia: Pentoxyfylline Suppresses the Activation of 20S and 26S Proteasomes in Muscles from Tumor-Bearing Rats," MOL BIOL REP (1999) 26:95-101
	42.	Coux, O. <i>et al.</i> , "Structure and Functions of the 20S and 26S Proteasomes," AN REVIEW BIOCHEM (1996) 65:801-847
	43.	Craiu, A. <i>et al.</i> , "Lactacystin and Clasto-Lactacystin $\beta$ -Lactone Modify Multiple Proteasome $\beta$ -Subunits and Inhibit Intracellular Protein Degradation and major Histocompatibility Complex Class I Antigen Presentation," J BIOL CHEM (1997) 272:13437-13445
	44.	Cui <i>et al.</i> , "Lovastatin Prevents Steroid-Induced Adipogenesis and Osteoporosis," ASBMR 18th Annual Meeting (September 1996) J BONE MINER RES (1996) 11(S1):S510
	45.	Ducy <i>et al.</i> "Increased Bone Formation in Osteocalcin-deficient Mice," NATURE (1996) 382:448-452
	46.	Edelman <i>et al.</i> , "Controlled and Modulated Release of Basic Fibroblast Growth Factor," BIOMATERIALS (1991) 12:619-626
	47.	Elofsson <i>et al.</i> , Chemistry & Biology (1999) 6:811-822
	48.	Ferretti, "Perspectives of pQct Technology Associated To Biomechanical Studies in Skeletal Research Employing Rat Models," BONE (1995) 17:353S-364S
	49.	Figueiredo-Pereira <i>et al.</i> , "A New Inhibitor of the Chymotrypsin-Like Activity of the Multicatalytic Proteinase Complex (20S Proteasome) Induces Accumulation of Ubiquitin-Protein Conjugates in a Neuronal Cell," J NEUROCHEM (1994) 63:1578-1581
	50.	Franzoso <i>et al.</i> , "Requirement for NF- $\kappa$ B in Osteoclast and B-Cell Development," GENES AND DEV (1997) 11:3482-3496
	51.	Garrett <i>et al.</i> , "Specific Inhibitors of the Chymotryptic Component of the Proteasome are Potent Bone Anabolic Agents In Vivo" Journal of Bone and Mineral Research (2000) 15(Suppl.1):S197
	52.	Gat <i>et al.</i> , "De Novo Hair Follicle Morphogenesis and Hair Tumors in Mice Expressing a Truncated $\beta$ -Catenin in Skin," CELL (1998) 95:605-614
	53.	Ghosh-Choudhury <i>et al.</i> , "Immortalized Murine Osteoblasts Derived from BMP 2-T-Antigen Expressing Transgenic Mice," ENDOCRINOLOGY (1996) 137:331-339
	54.	Gowan <i>et al.</i> , "Actions of Recombinant Interleukin 1, Interleukin 2, and Interferon- $\gamma$ on Bone Resorption in Vitro," J IMMUNOL (1986) 136:2478-2482
	55.	Groll <i>et al.</i> , J. Am. Chem. Soc. (2000) 122:1237-1238
	56.	Guijarro <i>et al.</i> , "Lovastatin Inhibits Lipopolysaccharide-induced NF- $\kappa$ B Activation in Human Mesangial Cells," NEPHROL DIAL TRANSPLANT (1996) 11:990-996
	57.	Gupta <i>et al.</i> , "Oral Cyclosporine for the Treatment of Alopecia Areata," J AMER ACAD OF DERMATOLOGY (1990) 22(2):242-250

**EXAMINER:**

Realtor

**DATE CONSIDERED:**

6/25/03

**EXAMINER:** Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

O I P E  
APR 01 2002  
SEARCHED  
TRADEMAKES  
697

Docket Number 432722002601

Application Number 10/050,425

Applicant

Gregory R. MUNDY et al.

Filing Date January 15, 2002

Group Art Unit 1646

Mailing Date March 22, 2002

APR 03 2002  
TECH CENTER 1600/2000

✓ 58.	Hardy et al., "The Secret Life of the Hair Follicle," TRANS GENET (1992) 8:55-61
59.	Harris et al. "Effects of Transforming Growth Factor $\beta$ on Bone Nodule Formation and Expression of Bone Morphogenetic Protein 2, Osteocalcin, Osteopontin, Alkaline Phosphatase, and Type I Collagen mRNA in Long-Term Cultures of Fetal Rat Calvarial Osteoblasts," J BONE MINER RES (1994) 9:855-863
60.	Hilt, W. et al., "Proteasomes: Destruction as a Programme," TRANS BIOCHEM SCI 91996) 21:96-101
61.	Iotsova et al., "Osteopetrosis in Mice Lacking NF- $\kappa$ B1 and NF- $\kappa$ B2," NATURE MED (1997) 3:1285-1289
62.	Jensen, T.J. et al., "Multiple Proteolytic Systems, Including the Proteasome, Contribute to CFTR Processing," CELL (1995) 83:129-135
63.	Kamiya et al., J. Derm. Sci. (1998) 17:54-60
64.	Kim et al., "Preparation of Multivesicular Liposomes," BIOCHIM BIOPHYS ACTA (1983) 728:339-348
65.	Kimmel et al., "The Effect of Recombinant Human (1-84) or Synthetic Human (1-34) Parathyroid Hormone on the Sleton of Adult Osteopenic Ovariectomized Rats," ENDOCRINOLOGY (1993) 132:1577-1584
66.	Ksander et al., "Exogenous Transforming Growth Factor-Beta 2 Enhances Connective Tissue Formation and Wound Strength in Guinea Pig Dermal Wounds Healing by Secondary Intent," ANN SURG (1990) 211(3):288-294
67.	Laval-Jeantet et al., "Dual-EnergyX-Ray Absorptiometry of the Calcaneus: Comparison with Vertebral Dual-Energy X-Ray Absorptiometry and Quantitative Computed Tomography," CALCIF TISSUE INTL (1995) 56:14-18
68.	Law et al., Mol. Cell Biol. (1992) 12:103-111
69.	Leserman et al., "Targeting to Cells of Fluorescent Liposomes Covalently Coupled With Monoclonal Antibody or Protein A," NATURE (1980) 288:602-604
70.	Liptay et al., "Inhibition of Nuclear Factor-Kappa B and Induction of Apoptosis in T-Lymphocytes by Sulfasalazine," BR J PHARMACOL (1999) 128(7):1361-1369
71.	Lutz, "Effects of Cyclosporin A on Hair," SKIN PHARMACOLOGY (1994) 7:101-104
72.	Majeska et al., "Maintenance of Parathyroid Hormone Response in Clonal Rat Osteosarcoma Lines," EXP CELL RES (1978) 111:465-467
73.	Maupin-Furlow, J.A. et al., "A Proteasome from the methanogenic Archaeon Methanosaeca thermophila," J BIOL CHEM (1995) 270:28617-28622
74.	Mayer et al., "Vesicles of Variable Sizes Produced by a Rapid Extrusion Procedure," BIOCHIM BIOPHYS ACTA (1986) 858:161-168
75.	Meng et al., "Epoxomicin, a Potent and Selective Proteasome Inhibitor, Exhibits In Vivo

EXAMINER:

R. G. Gromer

DATE CONSIDERED:

6/25/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

RECEIVED  
U.S. PATENT & TRADEMARK OFFICE  
APR 01 2002  
1697

Docket Number 432722002601

Application Number 10/650,426

## Applicant

Gregory R. MUNDY et al.

Filing Date January 15, 2002

Group Art Unit

Mailing Date March 22, 2002

TECH CENTER 1600/2000  
APR 03 2002

		Antiinflammatory Activity Proceedings of the National Academy of Sciences of the United States (1999) 96(18):10403-10408
RG	76.	Mundy et al., Science (1999) 286:1946-1949
	77.	Murray et al., "The Ubiquitin-Proteasome System and Cellular Proliferation and Regulation in Osteoblastic Cells," EXPERIMENTAL CELL RESEARCH (1998) 242:460-469
	78.	Olson et al., "Preparation of Liposomes of Defined Size Distribution by Extrusion Through Polycarbonate Membranes," BIOCHIM BIOPHYS ACTA (1979) 557:9-23
	79.	Orford et al., "Serine Phosphorylation-Regulated Ubiquitination and Degradation of $\beta$ -Catenin," J BIOL CHEM (1997) 272:24735-24738
	80.	Ozaki et al., "NF- $\kappa$ B Inhibitors Stimulate Apoptosis of Rabbit Mature Osteoclasts and Inhibit Bone Resorption by these Cells," FEBS LETTERS (1997) 410:297-300
	81.	Pahl et al., "The Immunosuppressive Fungal Metabolite Gliotoxin Specifically Inhibits Transcription Factor NF- $\kappa$ B," J EXP MED (1996) 183:1829-1840
	82.	Patent Abstracts of Japan (August 12, 1993) 17:436 (C-1096)
	83.	Patent Abstracts of Japan (June 20, 1987) 11:193 (C-430)
	84.	Patent Abstracts of Japan (April 25, 1986) 10:112 (C-342)
	85.	Peters, J. "Proteasomes: Protein Degradation Machines of the Cell," TRENDS BIOCHEM SCI (1994) 19: 377-382
	86.	Rickard et al., "Induction of Rapid Osteoblast Differentiation in Rat Bone Marrow Stromal Cell Cultures by Dexamethasone and BMP-2," DEVELOP BIOL (1994) 161:218-228
	87.	Sampath et al., "Isolation of Osteogenin, an Extracellular Matrix-Associated, Bone-Inductive Protein, by Heparin Affinity Chromatography," PROC NATL ACAD SCI USA (1987) 84:7109-7113
	88.	Sin, N. et al., "Total Synthesis of the Potent Proteasome Inhibitor Epoxomicin: A Useful Tool for Understanding Proteasome Biology," BIORG MED CHEM LETT (1999) 9:2283-2288
	89.	Szoka et al., "Procedure for Preparation of Liposomes With Large Internal Aqueous Space and High Capture by Reverse-Phase Evaporation," PROC NATL ACAD SCI USA (1978) 75:4194-4198
	90.	Tencer et al., "The Effect of Local Controlled Release of Sodium Fluoride on the Stimulation of Bone Growth," J BIOMED MAT RES (1989) 23:571-589
	91.	Vinitsky et al., "Inhibition of the Proteolytic Activity of the Multicatalytic Proteinase Complex (Proteasome) by Substrate-Related Peptidyl Aldehydes," J BIOL CHEM. (1994) 269(47):29860-29866
	92.	Wahl et al., "Sulfasalazine: A Potent and Specific Inhibitor of Nuclear Factor Kappa B," J CLIN INVEST (1998) 101(5):1163-1174
✓	93.	Wang et al., "Lipid Clearing Agents in Steroid-Induced Osteoporosis," J FORMOS MED ASSOC (1995) 94:589-592

EXAMINER:

R. G. Toman

DATE CONSIDERED:

6/25/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 432722002601

Application Number 10/050,425

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Gregory R. MUNDY *et al.*

APR 01 2002

Filing Date January 15, 2002

APR 03 2002

Mailing Date March 22, 2002

Group A Art Unit 1646

TECH CENTER 1600/2900

RL	94.	Wojcik <i>et al.</i> , "Ubiquitin-Mediated Proteolysis Centers in HeLa Cells: Indication from Studies of an Inhibitor of the Chymotrypsin-Like Activity of the Proteasome," EUR J CELL BIOL (1996) 71:311-318
RCG	95.	Wozney, "The Bone Morphogenetic Protein Family as Osteogenesis," MOLEC REPROD DEV (1992) 32:160-167

EXAMINER:

R. G. Sonnen

DATE CONSIDERED:

6/25/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.